



AJIT SRIVASTAVA (Rajit K Srivastava), Ph.D., FAHA, MBA (Visiting Prof. Univ Palermo, Italy & Wayne State University, Detroit, USA)

US address: 177 Addis Drive, Churchville, PA 18966
US Contact No. 215-396-1408 , 215-801-5129 (Cell)
ajitsriva@gmail.com

India Address: Executive Vice President & Head of Dept of Pharmacology & Biology
Piramal Life Sciences, 1 Nirlon Complex
Goregaon East, Mumbai- 400 063
India Contact No: 91-932-056-2175

Expertise: Advanced Biotechnology & Molecular Biology Education & Drug Discovery in Metabolic Diseases, Inflammation, Cardiovascular disease, Cell and Animal Model Development

SUMMARY OF QUALIFICATIONS

- Three decades of experience in research and teaching in India and in the US in the field of Biochemistry, Molecular Biology and Pharmacology, including generation of knockout and transgenic models to ask relevant biologic questions and to apply in drug discovery
- Experience of developing biotechnology courses for master level students in US
- Experienced leader in research and drug discovery with excellent track record and focus in diabetes, obesity, dyslipidemia, and inflammation using in vivo and in vitro models
- Experience of both academia and industry, and ability of formulating concepts and applying to drug discovery
- Experienced Leader in research and drug discovery with proven track record and focus in diabetes, obesity, dyslipidemia and atherosclerosis using in vivo and in vitro models
- Well established and widely known in the dyslipidemia, diabetes and atherosclerosis field
- Experience in providing direction on research initiatives/new drug targets, and project development
- Actively participated and provided leadership in preclinical research that resulted into taking two molecules to phase 1 clinical trial, one for diabetes and the other for reverse cholesterol transport indications
- Wrote scholarly scientific articles, chaired scientific sessions and gave invited seminars worldwide
- Wrote scientific reports and regulatory documents relating to IND filing for new drug entity
- Coordinated several project teams across functional areas
- Coordinated with Eli Lilly, Exelixis, and Isis Pharmaceuticals on joint projects in the metabolic disorders and cardiovascular disease area

- Actively participated in setting up a preclinical research facility in Bangalore as part of BMS-BIOCON collaboration. This included designing of the in vivo facility in metabolic diseases and inflammation therapeutic areas, recruiting biology head and group leaders in in vivo pharmacology.

PROFESSIONAL EXPERIENCE

Piramal Life Sciences, Mumbai, India

April 2008- Executive Vice President & Head of Pharmacology

PROFESSIONAL EXPERIENCE

Piramal Life Sciences, Mumbai, India

April 2008- Executive Vice President & Head of Pharmacology

Responsibilities at PLSL:

- Responsible for all Pharmacology-related efforts in diabetes, obesity, cardiovascular, and inflammation therapeutic areas.
- Provide scientific direction to all group leaders
- Critically review research data and provide scientific input during presentations
- Working closely with CEO to chalk out strategic plans, goals, time lines, resources and anticipated output
- Provide go/no go decision of programs based on scientific merits and doability
- Develop direct reports to prepare future leaders in drug discovery and preclinical development
- Interact on a regular basis with Scientists at Eli Lilly joint collaborative programs on Metabolic Disorders
- Actively involved in the evaluation of in-licensing and out-licensing packages
- Organize brain-storming sessions for scientists to encourage free scientific discussions

Bristol-Myers Squibb, Hopewell site, NJ, USA

July 6, 2004- April 2008 Head, Metabolic Diseases Pharmacology with focus on Lipid disorders, diabetes, obesity and atherosclerosis

Responsibilities at Bristol-Myers Squibb:

- * Led group of scientists to meet the challenges of the department focusing on HDL pathway, diabetes, obesity and assign responsibilities to the teams such that their expertise are fully utilized, and studies are completed in a timely manner without compromising quality
- * Coordinated with project team co-chairs to set up time lines, prioritize drug discovery efforts, provide input in designing experiments, and make sure that all biology and pharmacology needs of the ongoing projects are met
- * Reviewed study design and protocols, perform rigorous and critical analysis of data with appropriate interpretation, provide input to the discovery working team and give presentation to the senior management
- * Provided scientific inputs in terms of assay developments and animal model developments
- * Set up goals for direct reports and various teams, and mentored scientists for their career and leadership development
- * Provided scientific input in designing experiments, review targets, and collaborate with discovery working group
- * Directed PK/PD studies in mouse, rat, hamster, rabbit and cynomolgus monkeys.
- * Wrote several scientific reports on preclinical studies on early clinical candidates, and one report on IND filing

* Actively involved in in-licensing efforts and due diligence by visiting biotech and pharmaceutical companies and reviewing their data package

TULARIK (Amgen), South San Francisco, CA, USA

July 2002- June 2004 Head, In vivo Pharmacology

Accomplishments at Tularik (Amgen):

- * Proposed and evaluated targets for the treatment of diabetes and obesity.
- * Provided updates to the project teams and to the department on ongoing projects in development
- * Performed research and project reports writing
- * Developed cell-based assays and animal models for metabolic syndrome.
- * Designed, organized and performed experiments in various animal models including Zucker fatty, Zucker diabetic fatty and SD rats, ob/ob, db/db, and KKAy DIO mice
- * Developed in house DIO model for compound evaluation for antiobesity compounds
- * Developed hamster models for evaluating compounds for the treatment of dyslipidemia.
- * Established and developed animal models for CNS target in eating behavior.
- * Led a group of scientists and coordinated projects with 40 scientists
- * Coordinated and designed preclinical studies for five projects, two of them moved ahead for IND filing.
- * Actively involved in mechanism of compound action, establishing in vivo radioisotope and nonradioisotope methods for evaluation of lipid synthesis in various tissues
- * Directed PK/PD studies in the intact and cannulated rats.
- * Generated preclinical data of IND quality in several animal models of diabetes and obesity and wrote scientific reports.

WAYNE STATE UNIVERSITY, Dept. of Food Science and Nutrition

March 2002-2008 Adjunct Professor

UNIVERSITY OF PALERMO, Palermo, Italy

2007- Visiting Professor

ESPERION THERAPEUTICS, INC., Ann Arbor, USA

Jan, 2000- June 30, 2002 Director, Department of Pharmacology

March, 2000- Dec 2001 Senior Research Investigator, Biology

Accomplishments at Esperion Therapeutics::

- * Designed and performed in vivo and cell-based studies to determine the efficacy of lead compounds to treat dyslipidemia, diabetes, obesity, and atherosclerosis.
- * Gathered preclinical data to file patents and write a research report. An IND was submitted using these data, and clinical trial performed. Esperion was subsequently taken over by Pfizer.
- * Established cell-based moderate throughput screening of compounds for antidiabetic, antiobesity, insulin sensitizing, and triglyceride lowering activities.
- * Evaluated animal models for antiobesity, antidiabetic, antiatherosclerotic, and HDL elevating properties of lead compounds using Zucker fatty rats, Zucker diabetic fatty rats, ob/ob, db/db, and DIO mice. Carried out studies on atherosclerosis in LDL receptor and apoE KO mice.
- * Developed hepatocyte model for screening compounds that elevate apoAI and HDL and lower triglycerides and apoCIII using hepatocytes from transgenic mouse lines expressing either human apoAI or apoAI-CIII-AIV gene cluster.
- * Worked on early indicators of atherosclerosis to develop a rapid method to screen antiatherosclerotic compounds.

- * Proposed and validated new targets for drug discovery, and worked on elucidating mechanism of action of lead compounds.
- * Collaborated with scientists at academic institutions, wrote grant proposals and research papers, and lead several projects as study director.

Washington University- St. Louis, USA 1987-1999

1997-1999 Associate Professor of Medicine
 1992-1997 Assistant Professor of Medicine
 1989-1991 Research Instructor of Medicine
 1987-1989 Research Associate, Molecular Microbiology

Accomplishments at Washington University:

- * Formulated research projects on atherosclerosis, lipoprotein metabolism and molecular cell biology research, establishing scope and goals of projects and guiding individual team members in research activities to ensure goals were achieved.
- * Conducted weekly lab meetings in which team members presented research status, and facilitated problem solving and encouraged and evaluated new ideas.
- * Guided research on molecular cell biology of cholesterol transport and regulation of genes of lipid metabolism using in vivo and in vitro models, including genetically altered animal and cell models.
- * Developed and taught Molecular Cell Biology of Cholesterol Transport to first-year medical students.
- * Reviewed research papers related to molecular biology, physiology, lipid metabolism and nutrition for academic and international medical journals.
- * Maintained current knowledge of research activities and findings on international level, encouraging students and research assistants to do the same and guiding their professional presentations and scientific paper development.
- * Successfully developed, wrote and received funds based on research grant proposals.
- * Carried out studies on RNA processing in Escherichia coli.

University of Missouri, Saint Louis, USA

1997- 1999 Adjunct Professor

Responsibilities at University of Missouri

- Developed courses in Biotechnology and taught graduate students

Regional research Laboratory, Jorhat, India

1977- 1979 Senior Scientific Assistant (Biochemistry)
 1980- 1984 Senior Scientist (Biochemistry)

Accomplishments at RRL, Jorhat

- Successfully completed studies to isolate and identify starch hydrolyzing and hydrocarbon utilizing bacteria and purification of amylolytic enzymes and enzyme kinetics.
- Successfully proved hypothesis that thermostability of amylase can be enhanced considerably by chemical modification.
- Obtained useful intermediates including 17-ketosteroids used as a precursor in synthesis of steroid hormones, based on understanding of microbial transformation of plant sterols.
- Conducted research in tea biochemistry and microbiology

EDUCATION

B.Sc (Honours) Banaras Hindu University, Varanasi, India 1973

M.Sc, Biochemistry, Banaras Hindu University, Varanasi, India 1975

Ph.D., Biochemistry, India 1984

Postdoctoral training, Molecular Biology, Washington University, USA 1986-1989

HONORS AND AWARDS

- * Program Director- Wrote a grant proposal to Michigan Life Sciences Corridor Dec. 2001
- * Principal Investigator, Alzheimers Disease & Related Disorder Program 2000-2001
- * Initiated, wrote and received highly competitive grant for research.
- * Co-Principal Investigator on NIH Grant 1997-1999
- * Participated in grant writing and research requiring specific expertise.
- * Principal Investigator, Alzheimers Disease & Related Disorder Program 1997-1998
- * Initiated, wrote and received highly competitive grant for research.
- * Co-Investigator on NIH Grant 1993-1997
- * Participated in grant writing and research project requiring specific expertise.
- * Training Grant from the American Heart Association 1989-1991
- * Wrote and received grant for carrying out proposed research.
- * Senior Research Fellow 1981-1984
- * Frequently invited to speak at the national and international scientific conferences including key note address
- * Chaired sessions in scientific meetings
- * Guest Editor of special issue on Obesity (Bentham Scientific Publications) 2003-
- * Scientific advisory board of international scientific organizations. 2001-
- * Visiting Professor at the University of Palermo, Italy 2007-
- * Included in the Marquis 63rd Edition of Who's Who in America
- * Served as examiner of Ph.D. dissertations from students around the world
- * Organized gene expression technique workshop held in Italy and presented keynote address

PROFESSIONAL ORGANIZATIONS

- Fellow member of the American Heart Association
- Member, American Association for the Advancement of Science
- Member, American Diabetes Association
- Life member, Indian Atherosclerosis Society
- Life member, Indian Pharmacology Society
- Life member, Society of Biological Chemists, India

PUBLICATIONS

Research papers/presentations based on recent studies

1. **Srivastava, R.A.K.** (2007) Greater Inhibition of Atherosclerosis via HDL-independent Mechanism by PPAR α Agonist Compared to PPAR γ Agonist and Niacin in F1B Hamsters-ATVB Meeting, 2007. Manuscript under preparation for Atherosclerosis
2. Li, J, **Srivastava R A K** et al. Discovery of a Novel, Potent PPAR α Selective Activator BMS-687453. Presented at ACS, Boston, 2007. Manuscript in preparation
3. Ryan C, Zhang R, Monshizadegan H, Liu X, Yang R, Smalley J, Mukherjee R, Kirchgessner T, and **Srivastava R.A.K.** (2007) Selective Activation of PPAR- α Induces Fecal Cholesterol Excretion and Shows Synergistic Efficacy in Multiple Mouse Models When Combined with LXR Activation. Presented to AHA 2007. Manuscript ready to be sent.

4. **Srivastava, R.A.K.**, He, S., Zakin, M.M., Bisgaier, C.L., and Pape, M.E. Regulation of Apolipoprotein A1 and HDL by PPAR- α Activator and Cholic Acid in ApoAI and ApoAI-CIII-AIV Transgenic Mice Reveals Novel Mechanism. *J Lipid Res* (in preparation)
5. **Srivastava, R.A.K.** ATP-binding cassette transporter A1 (ABCA1): Is this a Druggable Target for treatment of metabolic syndrome x? (in preparation)

Peer-reviewed Published Papers

- 1 **Srivastava, R.A.K.** TNF-alpha down-regulates apoA1 gene expression and lowers HDL via interacting with the promoter of apoA1 gene. *Mol Cell Biochem* (under review)
- 2 **Srivastava, R.A.K.**, Ravi Jahagirdar, R, Adeli, K, and Bisgaier, C.L. Antiatherosclerotic, Antiobesity, Hypolipidemic and Insulin Sensitizing Activity of Fenofibrate in Golden Syrian Hamster. *J Pharm Exp Therap* (Under review)
- 3 Mukherjee, R, Locke, K.T., Miao, B, Meyers, D, Monshizadegan, H, Zhang, R, Search, D, Grimm, D, Flynn, M, Kevin M, O'Malley, K.M. Zhang, L, Li, J, Shi, Y, Kennedy, L.J., Michael Blonar, M, Cheng, P.T., Tino, J, **Srivastava, R.A.K.** Novel PPAR α agonists lower LDL and triglycerides, raise HDL and synergistically increase cholesterol excretion with an LXR agonist. *J Pharmacol Exp Therap*, 2008, 327(3):716-26.
- 4 **Srivastava, R.A.K.** Fenofibrate Ameliorates Diabetic and Dyslipidemic Profiles in KKAY Mice Partly via Down-regulation of *11- β HSD1* and *DGAT2*. *Comparison of PPAR α , PPAR γ , and LXR agonists*. *Eur J Pharmacol* 2009, 607 (2009) 258–263
- 5 Srivastava N, Averna, M, and **Srivastava, R.A.K.** Dietary cholesterol and estrogen administration elevate brain apolipoprotein E in mice by different mechanisms. *Ann Neurol Sci*. 2008, 15:89-93.
- 6 **Srivastava, R.A.K.** Jahagirdar, R, Azhar, S Sharma, S, and Bisgaier, C.L. Peroxisome proliferator-activated receptor- α -selective ligand reduces adiposity, improves insulin sensitivity, and inhibits atherosclerosis in LDL receptor-deficient mice. *Mol Cell Biochem*, 2006;285(1-2):35-50.
- 7 **Srivastava, R.A.K.** Scavenger receptor class B type I expression in murine brain and regulation by estrogen and dietary cholesterol. *J Neurol Sci (USA)* 2003, 210:11-18.
- 8 **Srivastava R.A.K.** and Srivastava, N. Search for obesity drugs: targeting central and peripheral pathways. *Curr Med Chem- Immunol Endoc Met Ag* 2004, 4:75-90.
- 9 **Srivastava, R.A.K.** Estrogen-induced regulation of the ABCA1 in mice: A possible mechanism of atheroprotection by estrogen. *Mol Cell Biochem*, 2002, 240:67-73.
- 10 **Srivastava, R.A.K.** and Jain, J.C. Scavenger receptor class B type 1 expression and elemental analysis in cerebellum and parietal cortex regions of the Alzheimer's Disease brain. *J Neurol Sci*, 2002, 196:45-52.
- 11 **Srivastava, R.A.K.**, Averna, M, Srivastava, N. and Pape. M.E.: Dietary cholic acid increases plasma levels of apolipoprotein B in mice by posttranscriptional mechanism. *Intern J. Biochem & Cell Biol (London)*, 2001; 33:1215-1226.
- 12 Srivastava, N., Chowdhury P., Maurizio, A., and **Srivastava, R.A.K.** Estrogen-induced lowering of plasma levels of high-density lipoproteins occurs via hepatic lipase-mediated pathway. *Mol Cell Biochem*, 2001; 220:87-93
- 13 **Srivastava, R.A.K.**, Srivastava, N., and Averna, M: Dietary cholic acid lowers plasma apolipoprotein AI primarily by transcriptional mechanism. *Eur J Biochem*, 2000; 267:4272-4280.
- 14 **Srivastava, R.A.K.**, and Srivastava, N: High-density lipoprotein, apolipoprotein A-I, and coronary artery disease. Review. *Mol Cell Biochem*, 2000; 209:131-144.
- 15 **Srivastava, R.A.K.** Apolipoprotein E gene expression is reduced in apolipoprotein A-I transgenic mice. *Mol Cell Biochem*, 2000; 209:125-129.

- 16 **Srivastava, R.A.K.**, Toth, L., Srivastava, N., Maeda, N. and Schonfeld, G: Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB. *Mol. Cell Biochem*, 1999; 202:37-46.
- 17 **Srivastava, R.A.K.**, Srivastava, N, and Schonfeld, G: Molecular bases of low production rates of apolipoprotein B-100 and truncated apoB-82 in a mutant HepG2 cell line generated by targeted modification of the apolipoprotein B gene. *J. Lipid Res*, 1999; 40:901-912.
- 18 **Srivastava, R.A.K.**: Analysis of RNA by Northern blotting using riboprobes. *Methods in Molecular Biology*, 1998; 86:103-112.
- 19 **Srivastava, R.A.K.**, Srivastava, N., Maurizio, A., Lin, R.C., Korach, K., Lubahn, D., and Schonfeld, G: Regulation of apolipoprotein E gene expression by estrogen occurs by translational mechanism via estrogen receptor mediated pathway. *J.Biol.Chem*, 1997; 272: 33360-33366.
- 20 **Srivastava, R.A.K.**, Krul, E.S., Lin, R.C., and Schonfeld, G: Regulation of lipoprotein metabolism by estrogen in inbred strains of mice occurs primarily at the posttranscriptional level. *Mol Cell Biochem*, 1997; 173:161-8.
- 21 Shaish, A., Pape, M., Rea, T., **Srivastava, R.A.K.**, Latour, M., Hopkins, D. and Schonfeld, G: Alcohol increases plasma levels of cholesterol-diet-induced atherogenic lipoproteins and aortic atherosclerosis in rabbits. *Arteriosclerosis & Thrombosis*, 1997; 17:1091-1097
- 22 Pulai, J., Aversa, M., **Srivastava, R.A.K.**, Latour, M.A., Clouse, R.E., and Schonfeld, G: Normal intestinal dietary fat and cholesterol absorption, intestinal apoB mRNA levels, and apoB-48 synthesis in a hypobetalipoproteinemic kindred without any apoB truncation. *Metabolism*, 1997; **46**:1095-1100
- 23 **Srivastava, N.**, and Srivastava, R.A.K: Expression, purification and properties of recombinant E. coli ribonuclease III. *Biochem. & Molecular Biol Intern*, 1996; 39:171-180.
- 24 **Srivastava, R.A.K** and Srivastava, N.:The multifaceted roles of the RNA processing enzyme RNase III- A minireview. *Indian J. Biochem & Biophys.* 1996; 33:253-260.
- 25 **Srivastava, R.A.K.**: Regulation of apolipoprotein E by dietary lipids occurs by transcriptional and posttranscriptional mechanisms. *Mol. & Cell. Biochem*, 1996; 155:153-162.
- 26 **Srivastava, R.A.K.**, Bhasin, N., and Srivastava, N: Apolipoprotein E gene expression in various tissues of mouse and regulation by estrogen. *Biochem & Mol Biol Intern*, 1996; **38**:91-101.
- 27 Srivastava, N., Maurizio, A., **Srivastava, R.A.K.**, Latour, M., and Schonfeld, G: A new apolipoprotein B truncation, apoB-43.7 in familial hypobetalipoproteinemia:Genetic and metabolic studies. *Metabolism*, 1996; **45**:1296-1304
- 28 **Srivastava, R.A.K.**: Increased apolipoprotein B100 mRNA by estrogen in inbred strains of mice occurs by decreased mRNA for RNA editing protein mRNA. *Biochem Biophys Res Commun*, 1995; 212:381-387.
- 29 **Srivastava, R.A.K.**, Ito, H., Matthias, H., Srivastava, N. and Schonfeld, G: Regulation of lowdensity lipoprotein receptor gene expression in HepG2 and Caco2 cells in response to palmitate, oleate and 25-hydroxycholesterol. *J Lipid Res*, 1995; 36:1436-1448.
- 30 **Srivastava, R.A.K.**, Kitchens, R.T. and Schonfeld, G: Regulation of apolipoprotein AIV by estrogen differs in rat and mouse. *European J Biochemistry*, 1994; 222:507-514
- 31 **Srivastava, R.A.K.**and Schonfeld, G: Quantification of absolute amounts of cellular messenger RNA by RNA-excess solution hybridization with riboprobes" *Methods in Molecular Biology. Protocols for Gene Analysis.* 1994, 31: 273-279.
- 32 **Srivastava, RAK.**: Dietary saturated fat, but not cholesterol, regulatess apolipoprotein A-I gene expression by posttranscriptional mechanism. *Biochem & Mol. Biol. Int.* 1994; **34**:393-402.

- 33 **Srivastava, R.A.K.** and Schonfeld, G: Measurements of rate of transcription in isolated nuclei by nuclear run-off assay" *Methods in Molecular Biology. Protocols for Gene Analysis*, 1994, 31: 281- 288.
- 34 **Srivastava, R.A.K.**, Baumann, D. and Schonfeld, G: In Vivo regulation of low density lipoprotein receptor by estrogen differs at the post-transcriptional level in rat and mouse. *European J Biochem*, 1993; 216:527-538.
- 35 **Srivastava, R.A.K.**, Tang, J., Baumann, D. and Schonfeld, G: Hormonal and nutritional stimuli modulate apolipoprotein B mRNA editing in mouse liver. *Biochem. Biophys. Res. Commun*, 1992; 188:135-141.
- 36 **Srivastava, R.A.K.**, Srivastava, N. and Schonfeld, G: Expression of low density lipoprotein receptor, apolipoprotein AI, AII and AIV in various rat organs utilizing an efficient and rapid method for RNA isolation. *Biochemistry International*. 1992; 27:85-95.
- 37 **Srivastava, R.A.K.**, Tang, J, Krul, ES, Pflieger, B, Kitchens, RT and Schonfeld, G: Dietary fatty acids and cholesterol differ in their effects on the in vivo regulation of apoAI and apoAII gene expressions in inbred strains of mice. *Biochim. Biophys. Acta*. 1992; 1125:251-261
- 38 **Srivastava, R.A.K.**, Srivastava, N and Apirion, D: Characterization of RNA processing enzyme RNase III from wild type and overexpressing *Escherichia coli* cells in processing natural RNA substrates. *International J. Biochemistry* 1992; 24:737-749.
- 39 **Srivastava, RAK**, Jiao, S, Tang, J, Pflieger, B, Kitchens, T, and Schonfeld, G: In vivo regulation of LDL receptor and apoB gene expressions in inbred strains of mice by dietary fatty acids and cholesterol. *Biochim Biophys Acta*, 1991; 1086:29-43.
- 40 **Srivastava, RAK** and Schonfeld, G: Using Riboprobes for Northern Blotting Analysis. *Bio/Techniques (U.S.A.)* 1991; 11:584-588.
- 41 Miczak, A., **Srivastava, R.A.K.**, and Apirion, D: RNA processing enzymes RNase III, E and P are located in the inner membrane of *E. coli*. *Molecular Microbiology*, 1991; 5:1801-1810.
- 42 **Srivastava, R.A.K.**, Pflieger, B. and Schonfeld, G.: Expression of LDL receptor, apolipoprotein B, apolipoprotein A1 and apolipoprotein AIV genes in various organs of mouse as determined by a novel solution hybridization assay. *Biochim. Biophys. Acta*. 1991; 1090: 95-101.
- 43 **Srivastava, R.A.K.**, Srivastava, N. and Apirion, D: RNA processing enzymes RNase III, E and P are not ribosomal enzymes. *Biochemistry International*.1991; 25:57-65.
- 44 **Srivastava, R.A.K.**: Effect of glycosylation of bacterial amylase on the active site conformation. *Indian J. Biochem. Biophys.* 1991; 28:108-113.
- 45 Tang, J, **Srivastava, RAK**, Krul, ES, Pflieger, B, Kitchens, T and Schonfeld, G: *In vivo* regulation of apolipoprotein A1 gene expression by estrogens and androgens occur by different mechanisms in inbred strains of mice. *J. Lipid Res.U.S.A.*, 1991; **32**:1571-1585.
- 46 **Srivastava, R.A.K.**: Studies on thermal stabilization of amylase by covalent coupling to soluble carbohydrates. *Enz. Microb. Technol. (U.S.A.)*, 1991; 13:164-170.
- 47 **Srivastava, R.A.K** and Schonfeld, G: A rapid and simple method for screening a large number of recombinant cDNA clones. *Bio/Techniques (U.S.A.)* 1990; 9:689-693.
- 48 **Srivastava, R.A.K** and Apirion D: Processing of precursor 10Sa RNA is a two step reaction: The first step is carried out by RNase III in the presence of Mn²⁺. *Biochimie*, 1990; 72:791-802.
- 49 **Srivastava, R.A.K.**: Taq DNA polymerase and polymerase chain reaction - A review. *J. Scient. Ind. Res.* 1990; 25:179-183.
- 50 **Srivastava, R.A.K.**: Purification and properties of amylases produced from *Bacillus stearothermophilus* strain. *Enz. Microb. Technol. USA*.1987; 9:749-754.
- 51 Khan, RH, **Srivastava, RAK**, and Rastogi, RC: Synthesis of new 5-substituted 4-phenyl 3-aryloxy methyl/phenyl/ethyl 1,2,4-triazoles and its antimicrobial activities. *Indian J. Pharm. Sc.* 1987; **49**:749-754

- 52 **Srivastava, R.A.K,** and Baruah, JN: Culture conditions for the production of amylase from *Bacillus stearothermophilus*. Appl. Env. Microbiol. (USA) 1986; 52:179-184.
- 53 **Srivastava, RAK:** Polyphenol oxidase activity in the development of acquired aroma in tea. Current Science 1986; **55**:284-287.
- 54 **Srivastava, S.K, Srivastava, RAK,** and Mathur, SN: Biotransformation of sugarcane sterols into ADD using a strain of *Arthrobacter globiformis*. J. Appl. Bacteriol. (London), 1985; 59:399-402.
- 55 Srivastava, SK, **Srivastava, RAK,** and Mathur, SN: Phytosterols from pressed mud residue after methanogenic fermentation. Experientia (Switzerland) 1985; **41**:524-525.
- 56 Khan, RH, **Srivastava, RAK,** and Rastogi, RC: Synthesis and antifungal/antibacterial activity of 3- aryloxy methyl-4 aryl 5-mercapto 2,4-steriozole and their thioglycolic acids. Indian J. Chem. 1985; **248**:883-885.
- 57 **Srivastava, RAK:** A spectrophotometric method for the estimation of caffeine and theophylline from tea leaves. Indian Drugs, 1985; **22**:424-426.
- 58 **Srivastava, RAK,** and Mathur, SN: Production of heat stable amylases by parent and mutant strains of *Bacillus stearothermophilus*. J. Indian Bot. Soc. 1985; **64**:98-100.
- 59 **Srivastava, R.A.K,** and Mathur, SN: Regulation of amylase biosynthesis in growing as well nongrowing cells of *Bacillus stearothermophilus*. J. Appl. Bacteriol. (London) 1984; 57:141-147.
- 60 **Srivastava, R.A.K:** Studies on extra and intracellular purified amylases from *Bacillus stearothermophilus*. Enzyme Microb. Technol. (USA) 1984; 6:422-426.
- 61 **Srivastava, RAK,** and Mathur, SN: Effect of media composition and concentrations on the synthesis and secretion of thermostable amylases from a thermophilic *Bacillus* sp. Indian J. Microbiol. 1984; **23**:110-116.
- 62 **Srivastava, RAK,** and Mathur, SN: Production of thermostable amylase from thermophilic *Bacillus* spp. Indian J. Microbiol. 1984; **24**:127-132.
- 63 **Srivastava, RAK,** Mathur, SN, and Baruah, JN: Purification and properties of intracellular amylases from a thermophilic *Bacillus* sp. AK-2. Acta Microbiologica Polonica 1984; **33**:57-66.
- 64 **Srivastava, RAK,** Srivastava, SK, and Mathur, SN: Extraction of phytosterols from pressed mud and its bio-conversion into 17-ketosteroids. Current Science 1983; **52**:823-824
- 65 Srivastava, JC, **Srivastava, RAK,** Srivastava, RC, and Mathur, SN: A weedicial principle from a weed, *C. axilaris*. Experientia (Switzerland) 1983; **39**:898-899.
- 66 **Srivastava, SK,** Srivastava, RAK, and Mathur, SN: A new report on a bacterium utilizing beta-sitosterol. Current Science 1982; **51**:1054.
- 67 **Srivastava, RAK,** Mathur, SN, and Devchoudhury, MN: Physiological aspects of different levels of nitrogen utilization in *Camellia sinensis* L. Indian J. Exp. Biol. 1982; **20**:208-212.
- 68 **Srivastava, RAK,** Nigam, JN, Pillai, KR, and Baruah, JN: Studies on amylase biosynthesis in growing and non-growing cells of a thermophilic *Bacillus* sp. Indian J. Exp. Biol. 1981; **19**:271-276.
- 69 **Srivastava, RAK,** Nigam, JN, Pillai, KR, and Baruah, JN: Production of high heat stable amylase from thermophilic *Bacillus* sp. Indian J. Microbol. 1981; **21**:131-139.
- 70 **Srivastava, RAK,** Nigam, JN, Pillai, KR, and Baruah, JN: Effect of certain carbohydrates, pH and temperature on the differential synthesis of alpha and beta-amylases by a thermophilic *Bacillus* sp. Indian J. Microbiol. 1981; **21**:251-258.
- 71 **Srivastava, RAK,** Nigam, JN, Pillai, KR, and Baruah, JN: Purification, properties and regulation of amylases produced by a thermophilic *Bacillus* sp. Indian J. Exp. Biol, 1980; **18**:972-976.
- 72 Chakraborty S, **Srivastava, RAK,** and Devchoudhyry, MN: Distribution of free amino acids and chlorogenic acids in different parts of "two leaves and a bud" and its relation to tea quality. Two & A Bud 1978; **25**: 17-21.

73 Chakraborty S, and **Srivastava RAK**: Biochemical interpretation for the quality deterioration of rains teas. Two & A Bud. 1977; **24**: 31-32.

PRESENTATION IN INTERNATIONAL SCIENTIFIC MEETINGS

More than 50 presentations made in International scientific meetings. Abstracts were published.

Popular Science Articles

- 1 **Srivastava, R.A.K**: “How tea helps you” Science Gem, 1977, 51-55.
- 2 **Srivastava, R.A.K**: “How safe are hair dyes” Science Reporter, 1979, 16:428-429.
- 3 **Srivastava, R.A.K**, and Pillai, K.R: “The split gene mystery”. Science Gem, 1980,11:29-32
- 4 **Srivastava, R.A.K**, and Srivastava, N: “Carcinogens in food” Vigyan Pragati, 1980, 324:146-148.